Comparative Pharmacology
Head-to-head clinical analysis: CLOPRA YELLOW versus EMETE CON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOPRA YELLOW versus EMETE CON.
CLOPRA-"YELLOW" vs EMETE-CON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clopra (metoclopramide) is a dopamine D2 receptor antagonist and, at higher doses, a serotonin 5-HT4 receptor agonist, which enhances gastrointestinal motility and accelerates gastric emptying. It also has central antiemetic effects via D2 blockade in the chemoreceptor trigger zone.
Antiemetic; dopaminergic antagonist at D2 receptors in the chemoreceptor trigger zone; also exhibits anticholinergic and antihistaminic properties.
Adult: 25-50 mg orally 3-4 times daily; maximum 200 mg/day. For severe pain: 50-100 mg intramuscularly every 4-6 hours; maximum 300 mg/day.
12.5 mg intravenously over 30 seconds as a single dose; may repeat once after 1 hour if necessary.
None Documented
None Documented
8-12 hours in normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is 8-12 hours in adults with normal renal and hepatic function; may extend to 15-20 hours in elderly or patients with hepatic impairment.
Renal: 70% unchanged, Biliary/Fecal: 20% as metabolites, 10% other
Primarily hepatic metabolism (CYP2D6, CYP3A4) with <5% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 60-70% of metabolites, with renal elimination of metabolites constituting 25-35%.
Category C
Category C
Antiemetic/Prokinetic Agent
Antiemetic